New driver mutations in non-small-cell lung cancer
Authors:
Top Cited Papers
- 1 February 2011
- journal article
- review article
- Published by Elsevier in The Lancet Oncology
- Vol. 12 (2) , 175-180
Abstract
No abstract availableKeywords
This publication has 66 references indexed in Scilit:
- A mouse model for EML4-ALK -positive lung cancerProceedings of the National Academy of Sciences, 2008
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancersNature Medicine, 2008
- Somatic mutations affect key pathways in lung adenocarcinomaNature, 2008
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activityProceedings of the National Academy of Sciences, 2008
- MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinibProceedings of the National Academy of Sciences, 2007
- Characterizing the cancer genome in lung adenocarcinomaNature, 2007
- Raf kinases: Function, regulation and role in human cancerBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2007
- A transforming mutation in the pleckstrin homology domain of AKT1 in cancerNature, 2007
- BRAF mutation predicts sensitivity to MEK inhibitionNature, 2005
- Mutations of the BRAF gene in human cancerNature, 2002